Dyslipidemia Drugs Market Outlook - 2027
Dyslipidemia is the unhealthy or abnormal levels of one or more kinds of lipids (fats) in patients’ blood stream. Blood contains three main types of lipid namely high-density lipoprotein (HDL), Low-Density lipoprotein (LDL), and triglycerides. Dyslipidemia, it usually means patient’s HDL levels are too low or patient’s LDL levels and triglycerides are high. The HDL is the good cholesterol because it helps to remove LDL from your blood. High LDL and triglycerides levels increase the risk of a heart attack and stroke. Low levels of HDL cholesterol are linked to higher heart disease risks.
Dyslipidemia is divided into primary and secondary types. Primary dyslipidemia is inherited. Secondary dyslipidemia is an acquired condition. That means it develops from other causes, such as obesity or diabetes. The most commonly used medication to treat dyslipidemia is a statin. These medicines help reduce LDL levels by interfering with cholesterol production in the liver. Other non-statin drugs include ezetimibe (Zetia), fibrates, like fenofibrate, PCSK9 inhibitors.
COVID-19 scenario analysis:
Pharmaceutical and biotech companies together with governments around the globe are working to address the COVID-19 outbreak, from supporting the development of vaccines to planning for medicines supply chain challenges. Currently, around 115 vaccine candidates and 155 molecules are in the R&D pipeline. Moreover, commonly used drugs such as Hydroxychloroquine, have witnessed a dramatic surge in demand for the management of COVID-19. Such high demand for these drugs has presented huge opportunities for manufacturers of COVID-19 management drugs, as many developed countries are short of these drugs. Owing to the demand for vaccine and treatment drugs for COVID-19, the pharmaceutical and biotechnology industry is expected to witness a significant growth in the future.
Owing to such factors, COVID 19 is expected to have a significant impact on the Dyslipidemia drugs market.
Top impacting factors: Market Scenario Analysis, Trends, Drivers and Impact Analysis
The increase in the number of patients of dyslipidemia and diabetes pose the growth in the dyslipidemia drugs market. Increase in awareness of this disease through organizing various campaigns can drive the growth of the market. The governmental strategies to help the market may also fuel the dyslipidemia drugs market. The various new innovations in the drugs to treat the disease may also propel the growth of this market.
However, the requirement of great capital in the innovations for development in the field is posing as a restrain to the growth of the market.
New product launches to flourish the market:
- Sanofi, a French pharmaceutical company launched Praluent, a novel dyslipidemia therapy in Korea in collaboration with Aventis Korea. This new therapy will work toward inhibiting the binding of PCSK9 to low-density lipoprotein receptors (LDLRs). This innovation will be able to fuel the growth of the market.
- In January 2019, Amgen received approval for its proprietary drug Repatha from the National Medical Products Administration (NMPA) in China. The drug will be the first PCSK9 inhibitor medication for adults in China where the prevalence of dyslipidemia has increased in the recent past, triggering the demand for dyslipidemia therapeutics in the region.
Surge in usage in hospital applications:
Increase in the prevalence of dyslipidemia in the population, especially in the obese population, and growing awareness about dyslipidemia drugs that has been observed in the recent year will increase the demand for dyslipidemia drugs market. This increase in the awareness of new drug applications can surge the usage of dyslipidemia drugs in the hospital sector.
Key benefits of the report:
- This study presents the analytical depiction of the global dyslipidemia drugs industry along with the current trends and future estimations to determine the imminent investment pockets.
- The report presents information related to key drivers, restraints, and opportunities along with detailed analysis of the global dyslipidemia drugs market share.
- The current market is quantitatively analyzed to highlight the global dyslipidemia drugs market growth scenario.
- Porter’s five forces analysis illustrates the potency of buyers & suppliers in the market.
- The report provides a detailed global dyslipidemia drugs market analysis based on competitive intensity and how the competition will take shape in coming years.
Questions answered in the dyslipidemia drugs market research report:
- What are the leading market players active in the dyslipidemia drugs market?
- What the current trends will influence the market in the next few years?
- What are the driving factors, restraints, and opportunities in the market?
- What are the projections for the future that would help in taking further strategic steps?
Dyslipidemia Drugs Market Report Highlights
| Aspects | Details |
 By Drug Type |
|
 By DISTRIBUTION CHANNEL |
|
 By Region |
|
 Key Market Players | Mylan N.V., Abbott Laboratories., Pfizer, Inc., Shionogi & Co., Ltd., Merck & Co., Inc., Amgen, Inc., Bayer AG, Bristol-Myers Squibb Company, Novartis AG, AstraZeneca plc |
Loading Table Of Content...
